Kirk Huntsman

You know, I'll go on social media or Facebook and stuff, and you're just inundated with these, "Hey, do you have sleep apnea? Are you snoring? Well, here, try this device," or, "Use this," or, do this type of thing.

And now having been, uh, proudly a Vivos patient, I kinda look at it and say, "Snake oil." Would you just call Kirk Huntsman and really do something about your-

[laughs]

... your sleep apnea? It's amazing.

And all the naysayers and the people that shorted our stock are gonna wish they hadn't.

So lo- a lot of good things happening around here.

Kirk Huntsman, CEO of Vivos Therapeutics.

Ticker symbol is V-V-O-S.

I'm your host, Tim Gerdeman, Vice Chair and Co-Founder and Chief Marketing Officer of Water Tower Research.

In today's podcast episode, I'm being joined by Kirk Huntsman, CEO of Vivos Therapeutics, NASDAQ ticker symbol VVOS.

Also joining us is my WTR healthcare analyst, Robert Sassoon.

Vivos is a revenue stage medical technology company focused on developing and commercializing a suite of innovative diagnostic and non-surgical treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities, primarily OSA or obstructive sleep apnea, often referred to as the silent killer, which is estimated to affect as many as 90 million people in the US and 1 billion worldwide.